exenatide


Also found in: Medical, Wikipedia.
Related to exenatide: Pramlintide

ex·en·a·tide

 (ĕk′sĕn′ə-tīd′, ĭg-zĕn′-)
n.
An injectable drug that is a synthetic analog of a digestive hormone and stimulates insulin secretion when blood sugar levels are high, used to treat type 2 diabetes.

[exen(din-4), peptide found in the saliva of the Gila monster, of which exenatide is a synthetic version (ex(ocrine) + end(ocrine) + -in, due to the fact that it is an exocrine secretion with endocrine activity) + peptide.]
Translations

exenatide

n exenatida
References in periodicals archive ?
Once-weekly exenatide demonstrated a statistically significant improvement in glycaemic control between the two treatments as measured by hemoglobin A1c (HbA1c).
Alkermes and the investigational drug, exenatide once weekly.
NEW ORLEANS -- Exenatide, in a novel once-weekly formulation, resulted in simultaneous improvements in blood pressure, lipid levels, and body weight as well as glycemic control in a year-long study in 241 type 2 diabetic subjects.
Nasdaq: ALKS) today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations.
Long-term, injection-free treatment with ITCA 650, a continuous subcutaneous delivery of exenatide via DUROS device, leads to stable glycaemic and weight control for 48 weeks in metformin-treated type 2 diabetes
comparing subjects randomized to either exenatide once weekly or LantusA'
The Food and Drug Administration warned physicians to immediately discontinue use of exenatide (Byetta) if pancreatitis is suspected, saying that it has received reports of six cases of necrotizing or hemorrhagic pancreatitis--including two deaths--since October 2007.
If exenatide works as well in a larger study, it might substitute for insulin injections.
About ITCA 650 ITCA 650 therapy for type 2 diabetes involves the continuous subcutaneous delivery of exenatide from a matchstick-size, miniature osmotic pump that is placed subcutaneously to provide continuous and consistent drug therapy.
LISBON - Reasonably similar glucose-lowering effects and modest weight loss can be achieved in patients with type 2 diabetes who are treated with a once-weekly, extended-release formulation of exenatide or once-daily liraglutide, the DURATION-6 study results show.
Food and Drug Administration's database for adverse events reported between 2004 and 2009 among patients using the drugs sitagliptin and exenatide.
of three different doses (5 mg, 8 mg and 11 mg) of exenatide once